Detalles de la búsqueda
1.
First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer.
N Engl J Med;
383(21): 2018-2029, 2020 11 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-33207094
2.
Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial.
Lancet Oncol;
22(4): 450-462, 2021 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-33794205
3.
Plain language summary of the CROWN study comparing lorlatinib with crizotinib for people with untreated non-small cell lung cancer.
Future Oncol;
17(34): 4649-4656, 2021 Dec 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34585621
4.
Lorlatinib in previously treated anaplastic lymphoma kinase-rearranged non-small cell lung cancer: Japanese subgroup analysis of a global study.
Cancer Sci;
111(10): 3726-3738, 2020 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-32681682
5.
Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1-2 trial.
Lancet Oncol;
20(12): 1691-1701, 2019 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-31669155
6.
Clinical Management of Adverse Events Associated with Lorlatinib.
Oncologist;
24(8): 1103-1110, 2019 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-30890623
7.
Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study.
Lancet Oncol;
19(12): 1654-1667, 2018 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-30413378
8.
Evaluation of the Effect of Lorlatinib on CYP2B6, CYP2C9, UGT, and P-Glycoprotein Substrates in Patients with Advanced Non-Small Cell Lung Cancer.
Clin Pharmacokinet;
63(2): 171-182, 2024 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-38079095
9.
Factors Associated With Developing Neurocognitive Adverse Events in Patients Receiving Lorlatinib After Progression on Other Targeted Therapies.
J Thorac Oncol;
18(1): 67-78, 2023 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36184067
10.
Efficacy of Lorlatinib in Treatment-Naive Patients With ALK-Positive Advanced NSCLC in Relation to EML4::ALK Variant Type and ALK With or Without TP53 Mutations.
J Thorac Oncol;
18(11): 1581-1593, 2023 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-37541389
11.
Lorlatinib with or without chemotherapy in ALK-driven refractory/relapsed neuroblastoma: phase 1 trial results.
Nat Med;
29(5): 1092-1102, 2023 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-37012551
12.
Patient-reported outcomes from the randomized phase 3 CROWN study of first-line lorlatinib versus crizotinib in advanced ALK-positive non-small cell lung cancer.
Lung Cancer;
174: 146-156, 2022 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-36410210
13.
Post Hoc Analysis of Lorlatinib Intracranial Efficacy and Safety in Patients With ALK-Positive Advanced Non-Small-Cell Lung Cancer From the Phase III CROWN Study.
J Clin Oncol;
40(31): 3593-3602, 2022 11 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35605188
14.
Lorlatinib Exposure-Response Analyses for Safety and Efficacy in a Phase I/II Trial to Support Benefit-Risk Assessment in Non-Small Cell Lung Cancer.
Clin Pharmacol Ther;
110(5): 1273-1281, 2021 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-33973232
15.
Palbociclib and cetuximab compared with placebo and cetuximab in platinum-resistant, cetuximab-naïve, human papillomavirus-unrelated recurrent or metastatic head and neck squamous cell carcinoma: A double-blind, randomized, phase 2 trial.
Oral Oncol;
115: 105192, 2021 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-33571736
16.
Brain Penetration of Lorlatinib: Cumulative Incidences of CNS and Non-CNS Progression with Lorlatinib in Patients with Previously Treated ALK-Positive Non-Small-Cell Lung Cancer.
Target Oncol;
15(1): 55-65, 2020 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-32060867
17.
Impact of lorlatinib on patient-reported outcomes in patients with advanced ALK-positive or ROS1-positive non-small cell lung cancer.
Lung Cancer;
144: 10-19, 2020 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-32344248
18.
ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer.
J Clin Oncol;
37(16): 1370-1379, 2019 06 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30892989
19.
Response to "Lorlatinib Exposed: A Far from Optimal Dose".
Clin Pharmacol Ther;
111(6): 1197-1198, 2022 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-35358326
20.
Rare expression of epithelial cell adhesion molecule on residual micrometastatic breast cancer cells after adjuvant chemotherapy.
Clin Cancer Res;
9(7): 2598-604, 2003 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-12855636